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Abstract:  
 
Due to the contribution of drug-target binding kinetics to drug efficacy, there is a high 
level of interest in developing methods to predict drug-target binding kinetic 
parameters. During the review period, a wide range of enhanced sampling molecular 
dynamics simulation-based methods has been developed for computing drug-target 
binding kinetics and studying binding and unbinding mechanisms. Here, we assess the 
performance of these methods considering two benchmark systems in detail: mutant 
T4 lysozyme-ligand complexes and a large set of N-HSP90-inhibitor complexes. The 
results indicate that some of the simulation methods can already be usefully applied 
in drug discovery or lead optimization programs but that further studies on more high-
quality experimental benchmark datasets are necessary to improve and validate 
computational methods. 
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Introduction  
 
The realization that drug binding kinetic parameters can be key determinants of drug 
efficacy in non-equilibrium in vivo conditions [1,2*], has led to interest in developing 
methods to compute ligand-receptor association (kon) and dissociation (koff) rate 
constants. Two years ago, we reviewed emerging computational methods [3] and 
noted that most of these had been applied to and validated on very small datasets, 
sometimes only one protein-ligand complex.  Over the last two years, the period of 
focus of this review, the rate of publication of methods to study binding kinetics has 
burgeoned. Some of these studies continue to be based on small datasets and have 
focused on exploring mechanistic aspects of binding kinetics by molecular simulation 
approaches. These studies are exemplified by eleven publications on a T4 lysozyme 
(T4L) mutant with a buried cavity in which benzene derivatives bind. We compare the 
approaches taken and the results obtained in the next section.  
The emergence of larger, systematically measured sets of kinetic data and structures 
of protein-ligand complexes provides a basis for developing computational methods 
suitable for deriving quantitative structure-kinetics relationships (QSKRs) and for their 
application in the lead optimization stage of drug discovery. Some of these studies aim 
at employing statistical machine learning or chemometric approaches to exploit 
structural information on protein-ligand complexes to derive QSKRs. However, the 
majority of the methods published in the last two years employ molecular dynamics 
(MD) simulation combined with enhanced sampling techniques. The most well-
studied of these datasets is that for heat shock protein 90 (N-HSP90) inhibitors. Below, 
we compare the studies done on N-HSP90 inhibitors, the different methods, their 
performance and mechanistic insights.  
By focusing on two selected protein targets, we aim to provide a practically relevant 
assessment of the current state of the field of computing binding kinetics, mechanisms 
and QSKRs. In this brief article, it is not possible to describe in detail all the relevant 
methods or the systems to which such methods have been applied. We therefore refer 
the reader to several recent reviews [2,4*–6] as well as to the on-line toolbox, KBbox 
[7] (kbbox.h-its.org), which contains descriptions of the different methods, along with 
some tutorials and guidance on usage. 
 
Exploring ligand pathways and associated kinetic rates: the L99A T4 
lysozyme mutant  
The L99A mutant of T4L has an engineered, buried cavity that can accommodate 
benzene derivatives (see Figure 1). Although it is not a drug target, T4L has been used 
as a model system to study protein-ligand binding, due to the small size and rigidity of 
the ligands and their fast binding and unbinding rates (with residence times,  τ 
(=1/koff), on the millisecond timescale for benzene and indole [8]). However, 
understanding T4L-ligand binding processes poses challenges for computational 
studies such as sufficiently sampling the protein conformational changes necessary to 
make the buried cavity accessible to ligands. The question of how many paths are 
available for ligand binding to and unbinding from T4L has been addressed in several 
recent studies. Complete sampling of ligand paths is important for calculating 
(un)binding rates. Moreover, knowledge of ligand paths and the associated 
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(un)binding mechanisms can guide the design of ligands or proteins with altered 
binding kinetics.  Ligand passage to and from binding sites cannot be directly observed 
experimentally and thus simulation methods have an important role in allowing such 
paths to be identified, visualized and quantitatively understood. 
 
 De novo detection of tunnels and enhanced sampling of binding paths  
While binding of a ligand is often considered to occur by one pathway, computational 
studies of T4L show that multiple pathways exist and the number of paths identified 
varies between different studies, see Figure 1. The highest number of paths, eight, 
was identified by Capelli et al. using well-tempered metadynamics [9].  
In other studies, fewer paths were identified. This inconsistency may in part be due to 
the different definitions of the pathways. For example, Rydzewski and Valsson 
sampled five paths for benzene unbinding from T4L (CF, CD, FGH, HJ, DG) [10] and 4-
5 different unbinding paths for various benzene derivatives [11]. However, the 
authors noted [10] that four of the paths identified by Capelli et al. were subclasses of 
the path FGH, which had the widest tunnel width and is the one path observed in all 
studies.  Moreover, this pathway was suggested as the most probable by Feher et al. 
[12]. However, in these studies, pathways were classified by visual inspection, which 
may lead to differences due to subjectivity. 
Another reason for the observation of different numbers of pathways in different 
studies may be that some of the enhanced sampling procedures alter the energetic 
barriers to ligand binding and unbinding. Indeed, in an unbiased MD study, three paths 
for benzene binding (FGH, HJ, DG) were observed whereas, in the same study 
infrequently biased metadynamics (InMetaD), in which the transition state should not 
be affected by the addition of potential terms to enhance sampling along collective 
variables, two paths (FGH, HJ) for benzene unbinding were sampled [13]. 
A further reason for variations in the number of pathways is the ligand size and 
physicochemical properties. For instance, the binding of benzene and benzene 
derivatives to T4L was studied by Niitsu et al. using the generalized replica exchange 
with solute tempering (gREST) method together with a flat-bottomed potential to 
limit the sampling of ligand positions [14]. Two binding paths (DG and FGH) were 
identified with preferences for the paths depending on ligand size and indications that 
the binding of larger ligands through the preferred pathway (FGH) requires coupling 
with a weakly populated conformation of helix F.  Sampling of this excited state was 
however identified in accelerated molecular dynamics (aMD) simulations as 
responsible for allowing benzene to exit through path FGH [12]. Indeed, nuclear 
magnetic resonance experiments on T4L [15,16] have shown a conformational 
exchange involving motion of helix F that occurs between the highly populated 
(crystallographic) structure and a weakly populated state on the millisecond 
timescale. This is the same timescale as that for benzene unbinding, and therefore the 
experiments and simulations together suggest that the ligand unbinding rate may be 
governed by the timescale of the accompanying protein motions.     
 
Computation of binding kinetic rates  
In only a few studies of T4L has pathway identification been quantitatively related to 
binding kinetics. These studies have employed methods of varying computational 
efficiency ranging from unbiased MD simulations to the use of machine learning to 
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enhance sampling. A recent example of the latter is reweighted autoencoded 
variational Bayes for enhanced sampling (RAVE) [17], where a neural network uses 
information from short unbiased MD simulations to learn progress coordinates. A 
variation of RAVE combined with the predictive information bottleneck (PIB) [18] 
framework  was developed and applied to benzene unbinding from T4L, resulting in 
one path (FGH) and a koff 100-fold lower than the experimental value [18,19*]. 
Weighted ensemble MD (WEMD)[20], which has recently been applied to computing 
the residence time of a drug with a long τ of 11 minutes [21*], yielded preliminary koff 
values for benzene unbinding from T4L 100-fold larger than the experimental value 
[22] (Table 1). In contrast, Mondal et al. [13] obtained koff values only 3-fold lower 
than the experimental value using unbiased MD simulations or InMetaD. A similar 
accuracy was achieved by Wang et al. [23] using InMetaD or frequency-adaptive 
metadynamics (FaMetaD).  
The most accurate koff estimation [13] was achieved with sampling of two unbinding 
paths (FGH, HJ), whereas the less accurate methods sampled one (FGH) [18] or four 
(FGH, CF, CD, HJ) paths [22].  Indeed, the rates computed for the four paths with 
WEMD were similar within standard error, indicating that these four paths may be 
relevant to the binding process. Rydzewski and Valsson also found quite similar 
unbinding times and average radii for these benzene unbinding paths [10]. 
Nevertheless, taken together, these results indicate that good koff estimations can be 
achieved without exhaustive path sampling so long as some of the most probable 
paths are sampled. Moreover, methods with low computational cost, such as InMetaD 
and FaMetaD [13,23], are able to provide estimates as accurate as methods of high 
computational cost, such as unbiased MD simulations.   
 
Computation of residence times for a highly flexible protein binding site: 
Heat Shock Protein 90 (N-HSP90) inhibitors. 
 
 A consistent benchmark dataset of kinetic rate constants measured by SPR for 104 
N-HSP90 inhibitors  
Recently, a large set of binding kinetics data measured by surface plasmon resonance 
(SPR) for drug-like inhibitors of the cancer target N-HSP90 has been made available 
[24–27]. These compounds bind in the ATP-binding site of the N-terminal domain of 
the protein (Figure 2A). The dataset has more than one hundred compounds that have 
kinetic rate constants ranging over 4 orders of magnitude for binding to N-HSP90 
(Figure 2B,[28]). Moreover, for at least 45 of these compounds, there are 
crystallographic structures of the complexes with N-HSP90 available with a resolution 
of 2 Å or better. An important characteristic of the N-HSP90 binding site is its flexibility. 
Depending on the ligand bound, it may adopt various conformations due to the 
plasticity of the α-helix 3 region, which undergoes different degrees of distortion in 
the vicinity of residue L107 (see Figure 2A).  The pure helical conformation is observed 
solely in a subset of the holo-structures, indicating stabilization of the protein 
secondary structure by the presence of a ligand in the binding site. Together with the 
large diversity of compounds in the dataset, the backbone and sidechain 
conformational variability of the protein binding site pose a significant challenge for 
the prediction of the dissociation mechanism and (un)binding rates.   
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Tradeoff between computational time and sensitivity for ligand unbinding 
simulations  
Several enhanced sampling MD methods for computing koff have been tested on 
different subsets of the N-HSP90 dataset: τRAMD [24][29*], targeted MD (TMD) 
[27][30], scaled MD [25] (Figure 3 and Table 1). Apart from one ligand simulated using 
dissipation-corrected targeted (dcTMD) [30], these studies provide relative values of 
τ or koff, with performance assessed by the correlation between experimental 
(log(koff)) and computed data (either unbinding energy [31] or work [27], or 
log(unbinding time) [25], [24]; see Table 1). In addition, a new complementary 
approach, CaverDock [32] [33], was applied to a set of 32 N-HSP90 complexes [31]. 
CaverDock is an adaptation of the Caver approach for detecting ligand egress routes 
in which ligand dissociation energy profiles are estimated by iteratively docking the 
ligand along the identified egress routes. Although, it is difficult to compare the 
performance of the different methods because the data employed in each case only 
partially overlap, it can be noted that the methods employing longer simulations (on 
the nanosecond time scale, i.e. [24] and [25]) generally resulted in better accuracy 
than those with shorter simulations ([27] and [31]). This observation corresponds with 
the expected tradeoff between the computational time (dependent on the magnitude 
of the sampling bias that speeds up dissociation) and the sensitivity of the methods to 
the underlying energy landscape, which is required for the reliable estimation of 
unbinding rates. As a result of the biases applied, there is incomplete agreement 
amongst these studies regarding the factors affecting the unbinding rate, the presence 
of a transition barrier (no barrier found by CaverDock [31] and a clear barrier in TMD 
[27]), and the dissociation pathways (e.g. the contribution of the alternative exit route 
to koff, Figure 2C). Importantly, because of a general correlation between koff and KD in 
the N-HSP90 inhibitor data set (Figure 2B), even simulations with a large uncertainty 
in the transition state may lead to a reasonable correlation between computed and 
experimental koff values.  
It is also noteworthy that the best agreement between computed and experimental 
data was observed for congeneric series of compounds (as highlighted in Refs. [24], 
[27] and [25]). This hints at cancellation of errors which may relate to deficiencies in 
the force fields employed, but also to the diversity of the mechanisms affecting τ 
which are not equally treated by the computational approaches employed. 
 
Consideration of protein dynamics in enhanced sampling MD simulations of 
unbinding rates  
In all the MD simulation studies of N-HSP90, prior knowledge of the binding site 
conformation (either loop- or helix-like shape of the α-helix 3 region) was employed. 
The only attempt to run calculations starting from an apo-structure of N-HSP90 was 
undertaken with Caverdock [31], but no correlation between computed and 
measured koff values was found. Moreover, the accuracy of the modeled structures of 
the protein-ligand complexes was shown to be critical for reliable MD simulations 
[24][31]. However, even if the crystal structure of the protein-ligand complex is 
available, additional exploration of the bound state, that cannot be fully sampled in 
short enhanced dissociation simulations, may be necessary for accurate computation 
of dissociation energies and unbinding rates. This problem is addressed in the 
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τRAMD[24] and TMD [27] protocols by performing multiple MD simulations to 
generate an initial equilibrium state ensemble prior to dissociation simulations.  
Protein dynamics is treated to different extents in the enhanced sampling methods. 
For example, restraining backbone motion completely (as in CaverDock [31]) or 
partially (as in scaled MD [25]) can impede ligand dissociation. Therefore, the latter 
method was re-designed in selectively scaled MD (ssMD) by scaling only the Lennard-
Jones potential between the ligand and water atoms to avoid the necessity to add 
protein restraints [34]. However, even without additional restraints, it is in general 
questionable whether biased MD is able to ensure the correct balance between the 
contributions of the slow and fast degrees of freedom of the system to the ligand 
unbinding process. 
 
QSKR models for N-HSP90 inhibition  
The large dataset of N-HSP90 inhibitors provides a good basis for developing statistical 
models aimed at the optimization of binding kinetics. Several such models have been 
reported recently for N-HSP90 – for prediction of τ from protein-ligand interaction 
fingerprints, PL-IFs, along dissociation trajectories [29] and  from binding energy terms 
for the bound complexes [35], and for prediction of kon from ligand desolvation 
energies [26]. The first two models are structure-based, which narrows their practical 
application. However, while a QSKR model dependent only on ligand properties might 
be preferable, it may require a large dataset and may never achieve the desired 
accuracy and interpretability. Despite a correlation between binding kinetic 
parameters and molecular weight being common (larger inhibitors of N-HSP90 tend 
to have slower binding kinetics than smaller compounds[36]), QSKRs can be expected 
to be strongly nonlinear since quite diverse factors have been reported to affect τ. In 
different subsets of the N-HSP90 dataset, these factors have included ligand fragment 
charge [27], ligand desolvation energy [29] and the degree of protein structural 
rearrangement required for ligand dissociation [24]. On the other hand, statistical 
models based on protein-ligand interactions provide an effective way to obtain insight 
into the molecular determinants and mechanisms underlying binding kinetics. For 
example, several studies (for N-HSP90 [29], p38 MAP kinase [37], and HIV-1 protease 
[38]) showed that the unbinding rate was determined by protein-ligand interactions 
in the first half of the dissociation process, which was also supported by a 
chemometric study [35] where koff, was found to be well predicted from the 
interactions of the bound state.  
 
Conclusions and future directions  
 
Taken together, the studies on the T4L and N-HSP90 datasets reviewed here provide 
a snapshot of the state-of-the-art of molecular simulations to study protein-ligand 
binding kinetics and their possible applications. The methods are being actively 
developed (recent examples include  ssMD [34], an extension of scaled MD, 
reweighting of ensembles by variance optimization (REVO) [39] based on WEMD, and 
FaMetaD [23] a modified metadynamics approach [23]). The methods address a range 
of needs. For example, a key distinguishing factor between simulation methods is 
whether they require user-choices about reaction coordinates and if so, which and 
how complex these choices are.  Another important difference is whether absolute or 
7 
 
relative values of koff are computed. The optimization of sampling for the computation 
of absolute values of koff by using different methods, including machine learning, has 
shown significant progress in reducing simulation time by about an order of 
magnitude, but these methods are still too computationally demanding for routine 
use and notably slower than the methods to compute relative koff values (such as 
τRAMD, TMD and scaled MD). The latter can be applied to a large range of koff values, 
often with better prediction accuracy, and thus, should be suitable for use in practical 
applications. Indeed, recently, elABMD, a method based on adiabatic bias MD, and 
scaled MD have, respectively,  been used prospectively to compute τ for a congeneric 
series of glycogen synthase kinase 3 beta inhibitors [40] and a small set of human D-
amino acid oxidase inhibitors [41]. In the next few years, we anticipate further method 
development and validation studies on a diverse range of relevant drug targets, as 
well as genuine applications of these methods in drug discovery projects.  The success 
of these studies will however rely on the availability of sizeable (kinetic rate 
measurements for > 30 compounds), high-quality datasets of protein-ligand binding 
kinetics. 
 
Glossary  
aMD – Accelerated molecular dynamics [12] 
dcTMD – Dissipation-corrected targeted MD [30] 
FaMetaD - Frequency-adaptive metadynamics [23] 
InMetaD - Infrequent metadynamics [13,23] 
MD - Molecular Dynamics simulations [24] 
MD+MSM – Unbiased Molecular Dynamics simulations and Markov State Model [13] 
MD+AMSM – Multiple MD simulations guided by Adaptive Markov state models  
(AMSM) [42] 
N-HSP90 – N-terminal domain of heat shock protein 90 
PIB - Predictive Information Bottleneck, an information theory method to learn a low-
dimensional representation of a system that has maximum predictive power [18] 
RAMD – Random acceleration molecular dynamics [43]  
RAVE - Reweighted autoencoded variational Bayes for enhanced sampling [17,19] 
REVO - Reweighting of Ensembles by Variance Optimization [39] 
τ – Residence time 
τRAMD – A protocol for obtaining relative residence times from RAMD simulations 
[24,29] 
QSKR - Quantitative structure-kinetics relationship  
SPR - Surface plasmon resonance 
TMD – Targeted MD [27] 
T4L – T4 lysozyme 
Scaled MD – scaled or smoothed MD in which the systems potential energy is scaled 
down [25,41] 
ssMD - Selectively scaled MD [34] 
WEMD – Weighted ensemble molecular dynamics [21,22] 
 
 
Acknowledgements 
8 
 
 
The authors thank Manuel Glaser and Dr. Goutam Mukherjee for suggestions on the 
manuscript. 
Funding: This work was supported by a Capes-Humboldt postdoctoral scholarship to 
A N-A (Capes process number 88881.162167/2017-01), the European Union’s Horizon 
2020 Framework Programme for Research and Innovation under Grant Agreement 
785907 (Human Brain Project SGA2) and the Klaus Tschira Foundation.  
 
Declaration of Interest 
 
The authors declare no conflict of interest.  
 
  
9 
 
Table 1:  Methods for computing ligand-receptor dissociation rates illustrated in Figure 3. 
Methods with recently published applications are listed and the simulation times given 
correspond to those in these applications.  
 
Method System  No. of 
compl
-exes 
Range of koff 
[s-1] 
Simulation accuracy 
 
Computation 
time per 
compound 1) 
[µs MD] 
Refer-
ences 
Pearson 
correlation 
coefficient 
R2 
Error 
factor 
(fold)  
PIB T4L 1 1 x 103 n.d. 100   ~ 0.1  [18] 
FaMetaD T4L 2 0.3-1 x 103 n.d. 2-5 2-5.5  [23] 
InMetaD 
InMetaD 
T4L 
T4L 
1 
1 
0.3 x 103 
1 x 103 
n.d. 
n.d. 
2 
3 
4.5  
n.d. 
[23] 
[13] 
WEMD T4L 1 1 x 103 n.d. 1-100 29  [22] 
MD + MSM T4L 1 1 x 103 n.d. 3 59  [13] 
TMD HSP90 25 1 x 10-4-0.5 0.45-0.8 n.d. 0.006  [27] 
τRAMD HSP90 70/92 1 x 10-4-0.5 0.78-0.72 ~2 0.004-0.4 [24]/ [29] 
Scaled MD HSP90 7 6 x 10-4-0.5 n.d. 4-20 0.2-7 [25] 
dcTMD HSP90 1 3 x 10-2 n.d. 20 ~1 [30] 
Caverdock HSP90 32 1 x 10-4-0.5 0.63 n.d. n.d.2) [31] 
Combine HSP90 70 1 x 10-4-0.5 0.8 ~2 n.d. 2) [35] 
 
1The simulation time depends on the properties of the system studied as well as the methods 
used. Only production/dissociation simulations are considered, not the system 
preparation/equilibration.  
2Methods that are not based on MD simulations. 
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Figures and captions 
 
Figure 1. Exit routes of benzene from the buried cavity in T4L identified in MD simulation studies. 
Two views of the structure of the complex (PDB ID 1L83 [44]) of T4L (in gray cartoon with helices 
labeled with black letters) and benzene (in orange ball and stick representation). The mutated 
A99 methyl group is shown in pink.  Paths for benzene (un)binding are denoted by arrows 
between the named helices. The arrows are colored according to how often the paths were 
found in the different studies (from dark blue (most frequent) through green and cyan to 
salmon (least frequent)): Path FGH: [9,10,12–14,18,19,22,45]; HJ: [9,10,13,22,45]; DG: 
[9,10,13,14,45]; CF, CD: [9,10,22,45]; FI, HIJ, EJ: [9]. 
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Figure 2: N-HSP90-inhibitor complexes provide a benchmark for the computation of binding 
kinetics. (A): N-HSP90 holo-structures have either helix-type (PDB ID 5J9X [36]) or loop-type 
(PDB ID 5J64 [46] and 1OSF [47]) conformations of the α-helix 3 segment (the corresponding 
ligand and flexible part of the α-helix 3 region are highlighted in cyan, magenta, and orange, 
respectively). (B): Plot of koff vs kon for 104 HSP90 inhibitors [28]. Cyan: helix-binders, magenta: 
loop-binders. (C): Representative dissociation routes for the compound shown in the inset (PDB 
ID 5LQ9[24]) generated in τRAMD simulations are shown by dots colored according to pathway: 
channel 1 (green) directly from the ATP binding site and channel 2 (pink) through the 
hydrophobic tunnel under α-helix 3. The latter pathway is observed only for a few compounds 
that occupy the hydrophobic sub-pocket under α-helix 3 and have a comparatively small moiety 
in the main ATP binding site (as shown in the inset).    
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Figure 3: Schematically illustration of the computational performance of MD simulation-based 
methods for computing protein-ligand dissociation rates. The simulated time required for 
computing koff is plotted in a log-log plot against the measured residence time for the following 
systems (with representative ligands shown above the plot):  benzene from T4L  (koff = 103 s-1 
[8]), benzamidine from trypsin (koff= 600 s-1[48]), inhibitors from HSP90 (koff = 10-4 s-1-0.8 s-1 ), 
and the TPPU inhibitor from soluble epoxide hydrolase  (koff = 1.5 10-3 s-1, absolute value 
computed by WExplore method[21] ); the computational data for T4L and HSP90 are 
summarized in Table 1, methods are defined in the Glossary.  Methods applied to multiple 
compounds are indicated by a set of points evenly distributed between the minimum and 
maximum koff values of the dataset used in the simulations. Methods that provide absolute 
unbinding rates and those that provide relative values are shown in red and blue color pallets, 
respectively.  
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